This NCI grant is for establishing Next Generation Chemistry Centers (NGC) focused on developing targeted therapeutic approaches for fusion oncoproteins in pediatric cancers. It funds independent research utilizing innovative chemical biology and chemoproteomic strategies to identify and develop small molecules. These compounds disrupt fusion oncoproteins by inhibiting their activities, blocking critical interactions, or inducing degradation. Outputs include chemical probes to potential drug candidates. Priority is given to applications targeting high-risk pediatric solid tumors and brain cancers, fostering collaborative efforts within NCI’s TFCC Network to accelerate novel treatment discovery.
Opportunity ID: 349313
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-23-037 |
| Funding Opportunity Title: | Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 17, 2023 |
| Last Updated Date: | Jul 17, 2023 |
| Original Closing Date for Applications: | Nov 15, 2023 |
| Current Closing Date for Applications: | Nov 15, 2023 |
| Archive Date: | Dec 21, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education County governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the UM1 mechanism to fund Next Generation Chemistry Centers (NGC) for Fusion Oncoproteins that have independent research projects using innovative chemical biology technologies and chemoproteomic approaches to target fusion-driven cancers. The goal of these discovery efforts will be to identify and develop small molecules that effectively disrupt fusion oncoproteins through mechanisms including, but not limited to, inhibiting activities of individual fusion oncoproteins, blocking critical fusion protein interactions, interacting with coding and/or noncoding RNAs required for fusion protein oncogenesis, and selectively inducing fusion protein degradation or degradation of proteins representing critical fusion oncoprotein dependencies. Compounds envisaged to be derived from these efforts may be either at the level of chemical probes and tools to delineate underlying biology, advanced leads to support further optimization to a candidate, or potential drug candidates themselves. In addition to the research proposed in their applications, each NGC Center will be expected to participate in collaborative projects with the U01s and potentially other members of the fusion oncoprotein community. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on high-risk pediatric solid tumors and brain cancers are particularly encouraged. UM1 recipients will meet regularly with U01 grantees funded through the Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers FOA. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-037.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 349313 Full Announcement-RFA-CA-23-037 -> RFA-CA-23-037-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282585 | Oct 15, 2023 | Nov 15, 2023 | View |
Package 1
Mandatory forms
349313 RR_SF424_5_0-5.0.pdf
349313 PHS398_CoverPageSupplement_5_0-5.0.pdf
349313 RR_OtherProjectInfo_1_4-1.4.pdf
349313 PerformanceSite_4_0-4.0.pdf
349313 RR_KeyPersonExpanded_4_0-4.0.pdf
349313 RR_Budget_3_0-3.0.pdf
349313 PHS398_ResearchPlan_5_0-5.0.pdf
349313 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349313 RR_SubawardBudget30_3_0-3.0.pdf
349313 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
